Login
Companies $CGTX
$0.65 +$0.01 (1.75%) After hours
COGNITION THERAPEUTICS INC logo

COGNITION THERAPEUTICS INC

cogrx.com

What Do They Do?

Develops small-molecule drug candidates for people with age-related degenerative diseases of the brain and retina, including Alzheimer’s disease and dementia with Lewy bodies.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +16% (Loss)
vs −$4.9M in Q3 FY2025

Focus on DLB psychosis The latest report prioritizes developing zervimesine for dementia with Lewy bodies psychosis; the earlier report described evaluating it as a disease-modifying treatment for dementia with Lewy bodies.

Geographic atrophy study ended The earlier report planned a clinical study for geographic atrophy secondary to dry age-related macular degeneration; the latest report says that study was concluded.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support